PS
IOVA icon

Principal Securities’s Iovance Biotherapeutics IOVA Stock Holding History

Principal Securities’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-127
Closed -$1.02K – 3490
2024
Q2 		$1.02K Sell
127
-12
-9% -$129 ﹤0.01% 3065
2024
Q1 		$2.06K Sell
139
-359
-72% -$4.18K ﹤0.01% 2866
2023
Q4 		$4.05K Buy
+498
New +$2.61K ﹤0.01% 2609

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Principal Securities's IOVA Position: Q3 2024 in Review

Principal Securities sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 127 shares — an estimated $1.02K sold.

Principal Securities first reported a position in IOVA in Q4 2023 and held it in 3 quarters. The position peaked at $4.05K in Q4 2023. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Principal Securities reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Principal Securities sold 127 Iovance Biotherapeutics shares in Q3 2024, an estimated $1.02K.
  • Principal Securities first reported a position in Iovance Biotherapeutics in Q4 2023 and held it in 3 quarters.
  • Principal Securities's Iovance Biotherapeutics position peaked at $4.05K in Q4 2023.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Principal Securities's 13F filing for Q3 2024, filed 28 Oct 2024.